leisure time -WSS

leisure time

author：leisure time 2025-10-01 23:57:16 - browse：8715

Vertex Pharmaceuticals Inc. building — Craig F. Walker/The Boston Globe

Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease.

The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

“The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： HHS names first

explore

WSS

Humans aren't the only ones with an imagination. Rats have it too

Medicare proceeds with plan to claw back hospital funds

Travis Kelce and the trap of celebrity vaccine endorsements

Generative AI mines health records to identify patients’ social needs

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Sarepta Duchenne therapy fails to meet primary endpoint in trial

hotspot

leisure time

Wikipedia

Cancer drug shortages should be causing more outrage

How I ended up pumping milk in a bathroom stall at JPM 2024

Alkermes shareholders re

After Sarepta trial failure, Duchenne families brace for more debate

As demand for Covid shots wanes, Moderna seeks its next success

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Supreme Court strikes down use of affirmative action

New Medicare drug pricing powers could soon be upended in court

How one medical school became remarkably diverse

New menopause drug shows promise in relief for hot flashes

Wikipedia

Life sciences investors close nearly $6 billion in new funds

How to convince healthy people to buy insurance

After Sarepta trial failure, Duchenne families brace for more debate

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

The SUPPORT Act is critical to fighting the opioid crisis

Sarepta Duchenne therapy fails to meet primary endpoint in trial

hotspot

explore

explore

hotspot